earningsconfidence high
BBOT Q1 net loss widens to $42.1M; cash $388.9M funds ops into 2028; pipeline shows early efficacy
BridgeBio Oncology Therapeutics, Inc.
2026-Q1 EPS reported
-$526.11
- Net loss $42.1M vs $22.1M YoY; R&D spend $39.8M on advancing three RAS programs.
- Cash, equivalents and marketable securities $388.9M as of March 31, 2026; runway into 2028.
- BBO-8520 monotherapy ORR 65% in KRAS G12C NSCLC; BBO-11818 partial response in pancreatic cancer.
- BBO-10203 achieved target engagement with no hyperglycemia; clinical benefit in CRC and HR+ BC.
- Pedro Beltran appointed CEO, Idan Elmelech COO effective April 20, 2026; Neil Kumar Executive Chairman.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.